<DOC>
	<DOCNO>NCT01282346</DOCNO>
	<brief_summary>To establish clinical performance SOLX Gold Shunt ability reduce intraocular pressure ( IOP ) eye refractory glaucoma medical conventional surgical treatment fail .</brief_summary>
	<brief_title>SOLX Gold Shunt Refractory Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<criteria>primary openangle glaucoma age 21 refractory glaucoma , IOP â‰¥ 24 mmHg medication fail prior incisional glaucoma surgery detectable visual field defect ( negative MD score ) write informed consent available 24 month followup either eye VA bad count finger angle closure glaucoma episode within past 12 month uveitic glaucoma , iridocorneal endothelial ( ICE ) syndrome , traumatic glaucoma , neovascular glaucoma diagnosis pigmentary glaucoma pseudoexfoliative glaucoma significant ocular disease , except cataract active ocular infection expect ocular surgery next 12 month suitable quadrant implant systemic corticosteroid therapy &gt; 5 mg/day prednisone intolerance gonioscopy eye exams mental impairment interfere consent compliance pregnancy know sensitivity anticipate medication use surgery significant comorbid disease concurrent enrollment another drug device study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Glaucoma shunt</keyword>
	<keyword>Ocular implant</keyword>
	<keyword>Gold</keyword>
	<keyword>Trabeculectomy</keyword>
</DOC>